Hemophilia Clinical Trial
Official title:
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
Haemophilia is a rare and serious congenital defect of blood coagulation due to a genetic
mutation on a sexual chromosome. It affects quasi-essentially the men and it is responsible
for bleeding. There are two types of haemophilia: Haemophilia A, (85 % of cases), due to a
factor VIII (FVIII) deficiency and Haemophilia B (15 % of cases) due to factor IX (FIX)
deficiency. According to the intensity of the defect, there are three forms of haemophilia:
severe (FVIII or FIX lower than 1 %), moderate (factor level between 1 and 5 %), minor
(factor level between 5 and 40 %). For a same level of factor VIII or IX, hemorrhagic
manifestations are variable from one patient to the other. Moreover, several studies showed
that haemophilic B patients bleed less and consume fewer anti-hemophilic concentrate that
haemophilic A patients.
The main inhibitors of the coagulation are antithrombin, Protein C-Protein S-Thrombomodulin
system, and tissue factor pathway inhibitor (TFPI). TFPI is the specific and exclusive
inhibitor of tissue factor pathway that is the main way by which plasmatic coagulation
starts. TFPI is a potent direct inhibitor of factor Xa and Xa-dependent inhibitor of the
VIIa-Tissue Factor (TF) complex. In hemophilic patient, the production of Xa by the
amplification pathway being strongly altered because of factor VIII or IX deficiency,
thrombin generation (via Xa) comes exclusively from TFPI regulated tissue factor pathway. We
can thus say that if haemophilic patients bleed, it is also because of the presence of TFPI
that inhibits at the same time Xa and the complex TF-VIIa as soon as factor Xa is generated.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05617209 -
In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
|
||
| Completed |
NCT05039008 -
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
|
N/A | |
| Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
| Unknown status |
NCT02433782 -
Myofascial Therapy in Patients With Hemophilic Arthropathy
|
N/A | |
| Completed |
NCT02165462 -
Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
|
N/A | |
| Terminated |
NCT02586012 -
Weight-based Dosing in Hemophilia A
|
Phase 2 | |
| Completed |
NCT02546622 -
ATHN 2: Factor Switching Study
|
||
| Unknown status |
NCT02165592 -
Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia
|
N/A | |
| Completed |
NCT01232634 -
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
|
Phase 2 | |
| Completed |
NCT05104164 -
Self-myofascial Release in Hemophilic Ankle Arthropathy
|
N/A | |
| Terminated |
NCT01191372 -
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
|
Phase 1 | |
| Completed |
NCT05173129 -
Posture Analysis for Patients With Haemophilia
|
N/A | |
| Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
| Withdrawn |
NCT03996486 -
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
|
Phase 1 | |
| Completed |
NCT01708564 -
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
|
Phase 1 | |
| Completed |
NCT03842605 -
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
|
N/A | |
| Completed |
NCT05549843 -
Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle
|
N/A | |
| Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT05027230 -
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|